| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Camrelizumab manufacturers
- Camrelizumab
-
- $163.00
-
2026-07-14
- CAS:1798286-48-2
- Purity: 98.60%
- Supply Ability: 10g
|
| | Camrelizumab Basic information |
| Product Name: | Camrelizumab | | Synonyms: | Camrelizumab;Camrelizumab (anti-PD-1);Research Grade Camrelizumab(DHH02211);SHR-1210;Research Grade Camrelizumab | | CAS: | 1798286-48-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Camrelizumab Structure]() |
| | Camrelizumab Chemical Properties |
| storage temp. | 4°C, Do not freeze, Protect from light. | | form | Solid | | color | White to light yellow |
| | Camrelizumab Usage And Synthesis |
| Uses | Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumabbinds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts asanti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al[1][2]. | | in vivo | Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice[1]. | | References | [1] Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. DOI:10.1136/jitc-2020-002191
[2] Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther DOI:10.2147/DDDT.S243787
[3] Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med.2021 Mar;9(3):305-314. DOI:10.1016/S2213-2600(20)30365-9 |
| | Camrelizumab Preparation Products And Raw materials |
|